Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Completed Phase 2 Interventional

Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD

NCT00648245
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
BIO-11006 Inhalation Solution, Placebo, BIO-11006
Drug
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Industry
Eligibility
45 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Glendale, Arizona • Los Angeles, California • Bay Pines, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Oct 17, 2026, 7:17 AM EDT
Completed No phase listed Observational

Long-term Observational Study of the Safety of Roflumilast

NCT03381573
View directory record Official record
Conditions
COPD
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
135,856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato Loxapine Pulmonary Safety in Patients With COPD

NCT00889837
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Inhaled Loxapine, Inhaled Placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
40 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 17, 2026, 7:17 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Astegolimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 90 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
68
States / cities
Birmingham, Alabama • Dothan, Alabama • Jasper, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Not listed Not applicable Interventional Results available

Gala Early Feasibility Study of RheOx

NCT03631472
View directory record Official record
Conditions
Chronic Bronchitis, Copd Bronchitis
Interventions
RheOx
Device
Lead sponsor
Gala Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Jacksonville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 17, 2026, 7:17 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

NCT01559051
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lipoaspiration with Local anesthesia
Procedure
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Stabilization of Hypercapnia: NIPPV v HVNI

NCT04709562
View directory record Official record
Conditions
Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Dyspnea, Hypercapnic Acidosis
Interventions
High Velocity Nasal Insufflation (HVNI), Noninvasive Positive Pressure Ventilation (NIPPV)
Device
Lead sponsor
Vapotherm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Oxnard, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Not applicable Interventional

Hospital-Level Care at Home for Acutely Ill Adults

NCT03203759
View directory record Official record
Conditions
Infection, Heart Failure, COPD, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Home hospitalization, Traditional inpatient hospitalization
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 17, 2026, 7:17 AM EDT
Not listed No phase listed Observational

The Epigenetics of Exercise and Physical Activity in COPD

NCT03539042
View directory record Official record
Conditions
Copd
Interventions
Not listed
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 17, 2026, 7:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fat Metabolism in OSA and COPD

NCT02157844
View directory record Official record
Conditions
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Obesity
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Supplemental Oxygen on Maximal Oxygen Consumption in Patients With Chronic Obstructive Pulmonary Disease

NCT01294033
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fractional inspired oxygen (FiO2) 0.21, Fractional inspired oxygen 0.28
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 17, 2026, 7:17 AM EDT
Enrolling by invitation Not applicable Interventional

Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia

NCT07512687
View directory record Official record
Conditions
Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Hypoxemia
Interventions
Portable Oxygen Concentrator, Portable compressed oxygen D-tanks, No ambulatory oxygen therapy
Device · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Phase 3 Interventional

Improving Clinician Communication Skills (ICCS)

NCT00687349
View directory record Official record
Conditions
Advanced Cancer, Chronic Obstructive Pulmonary Disease (COPD), Restrictive Lung Disease, Congestive Heart Failure, End Stage Liver Disease
Interventions
Training Program Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Charleston, South Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Phase 3 Interventional

Comparison of Two Programs to Encourage Physical Activity in Individuals With Chronic Obstructive Pulmonary Disease

NCT00328484
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
Lifestyle Activity Program, Exercise Program
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 17, 2026, 7:17 AM EDT
Recruiting Not applicable Interventional

PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.

NCT05306743
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CONQUEST Quality Improvement Program
Other
Lead sponsor
Observational and Pragmatic Research Institute
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Denver, Colorado • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Phase 2 Interventional

Dose-Ranging Study of A006 DPI, in Adult Asthma Patients

NCT01174732
View directory record Official record
Conditions
Asthma, Bronchospasm
Interventions
albuterol inhalation powder, Placebo, albuterol inhalation aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
San Jose, California • Centennial, Colorado • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Results available

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02138916
View directory record Official record
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
138
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 17, 2026, 7:17 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Temple Health Chest Initiative (THCI 2.0)

NCT06933758
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Determine COPD prevalence utilizing spirometry along with CT scans and symptom assessments in the THCI lung cancer screening populatio
Diagnostic Test
Lead sponsor
Temple University
Other
Eligibility
50 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 17, 2026, 7:17 AM EDT
Completed No phase listed Observational

Evaluating Genetic Factors That May Contribute to Elastin Function and the Development of Chronic Obstructive Pulmonary Disease

NCT00725309
View directory record Official record
Conditions
Emphysema, Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 17, 2026, 7:17 AM EDT
Terminated Phase 3 Interventional Results available

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

NCT00138671
View directory record Official record
Conditions
Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
Interventions
Subcutaneous Insulin, Inhaled Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 77 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
77
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Phase 1 Interventional

Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1

NCT01758744
View directory record Official record
Conditions
Pulmonary Hypertension, COPD
Interventions
Inhaled Treprostinil Therapy
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Results available

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03474081
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/UMEC/VI, Tiotropium, Albuterol/salbutamol, Placebo to match FF/UMEC/VI, Placebo to match tiotropium, ELLIPTA inhaler, HANDIHALER, MDI
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Andalusia, Alabama • Huntington Beach, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Results available

12 / 48 Week Pivotal PFT vs PBO in COPD I

NCT00782210
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI1744), placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
21
States / cities
Jasper, Alabama • Berkeley, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01202188
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Oct 17, 2026, 7:17 AM EDT